Eureka Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Eureka Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10562
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:32
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Eureka Therapeutics Inc (Eureka Therapeutics) is a clinical stage biotechnology company which focuses on the development of novel T cell immunotherapies for the treatment of solid tumors. Its pipeline encompasses drug candidates for various indications such as liver cancer, hematological cancer, lung cancer, head and cervical cancers, prostate cancer, multiple mylenoma, ovarian and peritoneal cancer, among others. Eureka Therapeutics utilizes its proprietary science platform ARTEMIS, which enables the discovery of fully-human antibodies against intracellular antigens via the MHC-peptide complex. The company collaborated with Memorial Sloan-Kettering Cancer Center for the joint discovery and research of new antibodies. Eureka Therapeutics is headquartered in Emeryville, California, the US.

Eureka Therapeutics Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Eureka Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Eureka Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Eureka Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Eureka Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Eureka Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 9
Eureka Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Eureka Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Eureka Therapeutics Raises USD20 Million in Venture Financing 11
Eureka Therapeutics Raises USD60 Million in Series D Financing 12
Eureka Therapeutics Raises USD26.6 Million in Venture Financing 13
Eureka Therapeutics Raises USD21 Million in Series C Venture Financing 14
Partnerships 15
Zhongyuan Union Cell & Gene Engineering to Form Joint Venture with Tibet Based Biotechnology Firm and Eureka Therapeutics 15
Janssen Biotech Enters into Agreement with Eureka Therapeutics 16
Boehringer Ingelheim Enters into Research Agreement with Eureka Therapeutics 17
Licensing Agreements 18
Boehringer Ingelheim Exercises Option for Licensing Agreement with Eureka Therapeutics 18
Juno Therapeutics Enters into Licensing Agreement with MSK and Eureka Therapeutics 19
Juno Therapeutics Enters into Licensing Agreement with Memorial Sloan Kettering Cancer Center and Eureka Therapeutics 20
Eureka Therapeutics And Memorial Sloan-Kettering Cancer Center Enter Into Licensing Agreement With Novartis 21
Eureka Therapeutics Inc – Key Competitors 23
Eureka Therapeutics Inc – Key Employees 24
Eureka Therapeutics Inc – Locations And Subsidiaries 25
Head Office 25
Recent Developments 26
Corporate Communications 26
Jul 16, 2018: Eureka Therapeutics Announces New Scientific Advisory Board Members 26
Apr 20, 2017: Eureka Therapeutics Expands Scientific Advisory Board with Appointment of Industry Leaders Dr. Hideho Okada and Dr. Nai-Kong Cheung 27
Product News 28
08/30/2018: Eureka Therapeutics to Present Proof-of-Concept Preliminary Data from Ongoing China Clinical Study of ET140202 at CAR-TCR 2018 Summit 28
Aug 16, 2018: Eureka Therapeutics announces publication of armored t-cell proof-of-concept study in nature biotechnology 29
Clinical Trials 30
Nov 27, 2017: Eureka Announces FDA Allowance of Investigational New Drug Application for ET190L1-ARTEMIS T cell Therapy in Relapsed and Refractory CD19+ Non-Hodgkin Lymphoma 30
Jun 07, 2017: Eureka Therapeutics and City of Hope Announce Agreement to Conduct Phase 1 Clinical Trial of Investigational ET1402L1 CAR-T Therapy in Liver Cancer 31
Appendix 32
Methodology 32
About GlobalData 32
Contact Us 32
Disclaimer 32

List of Tables
Eureka Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts 2
Eureka Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Eureka Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Eureka Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Eureka Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Eureka Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 9
Eureka Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Eureka Therapeutics Raises USD20 Million in Venture Financing 11
Eureka Therapeutics Raises USD60 Million in Series D Financing 12
Eureka Therapeutics Raises USD26.6 Million in Venture Financing 13
Eureka Therapeutics Raises USD21 Million in Series C Venture Financing 14
Zhongyuan Union Cell & Gene Engineering to Form Joint Venture with Tibet Based Biotechnology Firm and Eureka Therapeutics 15
Janssen Biotech Enters into Agreement with Eureka Therapeutics 16
Boehringer Ingelheim Enters into Research Agreement with Eureka Therapeutics 17
Boehringer Ingelheim Exercises Option for Licensing Agreement with Eureka Therapeutics 18
Juno Therapeutics Enters into Licensing Agreement with MSK and Eureka Therapeutics 19
Juno Therapeutics Enters into Licensing Agreement with Memorial Sloan Kettering Cancer Center and Eureka Therapeutics 20
Eureka Therapeutics And Memorial Sloan-Kettering Cancer Center Enter Into Licensing Agreement With Novartis 21
Eureka Therapeutics Inc, Key Competitors 23
Eureka Therapeutics Inc, Key Employees 24

List of Figures
Eureka Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Eureka Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Eureka Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Eureka Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Eureka Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Eureka Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Eureka Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Eureka Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Eureka Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Eureka Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Havells India Ltd (HAVELLS):電力:M&Aディール及び事業提携情報
    Summary Havells India Limited (Havells) is a fast moving electrical goods (FMEG) company that primarily designs, produces, distributes and sells a range of industrial and consumer electrical products. Its offers various consumer support and industrial electrical solutions support related products. T …
  • Shelby Energy Cooperative, Inc.:発電所・企業SWOT分析
    Shelby Energy Cooperative, Inc. - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on k …
  • The Norwegian Radium Hospital Research Foundation-製薬・医療分野:企業M&A・提携分析
    Summary The Norwegian Radium Hospital Research Foundation (RF) is a healthcare research hospital that provides clinical studies. The hospital conducts research programs and clinical studies. It offers services such as research and development. RF is a cancer research and rehabilitation center provid …
  • Glavbolgarstroy Holdings AD:企業の戦略・SWOT・財務情報
    Glavbolgarstroy Holdings AD - Strategy, SWOT and Corporate Finance Report Summary Glavbolgarstroy Holdings AD - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Northwest Pipe Co (NWPX):企業の財務・戦略的SWOT分析
    Northwest Pipe Co (NWPX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • St. James’S Place Plc:企業の戦略・SWOT・財務分析
    St. James'S Place Plc - Strategy, SWOT and Corporate Finance Report Summary St. James'S Place Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Avadel Pharmaceuticals Plc (AVDL):製薬・医療:M&Aディール及び事業提携情報
    Summary Avadel Pharmaceuticals Plc (Avadel), formerly Flamel Technologies SA is a specialty pharmaceutical company, which develops and commercializes drugs for allergy, asthma, central nervous system (CNS) (narcolepsy), pain, respiratory diseases and diabetes. The company’s products are built on its …
  • Gavilon Agriculture Holdings Co:石油・ガス:M&Aディール及び事業提携情報
    Summary Gavilon Agriculture Holdings Co (Gavilon) is a merchandising service provider that offers essential agricultural commodities and services. The company’s products include grains and oilseeds, feed ingredients, fertilizers, and food ingredients, among others. Its feed ingredients comprise anim …
  • Etam Developpement SCA:戦略・SWOT・企業財務分析
    Etam Developpement SCA - Strategy, SWOT and Corporate Finance Report Summary Etam Developpement SCA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Checkmate Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Checkmate Pharmaceuticals Inc (Checkmate Pharmaceuticals) is a clinical stage company that discovers and develops immunotherapies to provide new treatment options for patients and the healthcare providers. The company’s lead product candidate, CMP-001, is a CpG oligonucleotides (CpG-A ODN) t …
  • Bancolombia S.A.:企業の戦略・SWOT・財務情報
    Bancolombia S.A. - Strategy, SWOT and Corporate Finance Report Summary Bancolombia S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Intersect ENT Inc (XENT):医療機器:M&Aディール及び事業提携情報
    Summary Intersect ENT Inc (Intersect), formerly Sinexus Inc is a medical device company that offers chronic sinusitis solutions. The company offers steroid releasing implants and mini steroid implants. It provides surgical solutions for patients, disease recurrence with recurrent symptoms. Intersect …
  • Schneider National Inc (SNDR):企業の財務・戦略的SWOT分析
    Schneider National Inc (SNDR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Concur Technologies, Inc.:企業の戦略的SWOT分析
    Concur Technologies, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Michael J Fox Foundation for Parkinson’s Research:製薬・医療:M&Aディール及び事業提携情報
    Summary Michael J Fox Foundation for Parkinson's Research (Michael J. Fox) is a research foundation that conducts research on Parkinson's disease. The foundation offers research and development of therapies. It provides drug development and other research activities. Michael J. Fox offers treatments …
  • Nanosphere Inc-製薬・医療分野:企業M&A・提携分析
    Summary Nanosphere Inc (Nanosphere) a subsidiary of Cepheid is a medical device company that develops molecular diagnostic tests for disease detection and patient treatment. The company’s products comprise verigene system, instrumentation, bloodstream infection tests, gastrointestinal infection test …
  • Cesca Therapeutics Inc (KOOL):製品パイプライン分析
    Summary Cesca Therapeutics Inc (Cesca) researches, develops, and commercializes cell based therapeutics for applications in regenerative medicine. Its proprietary technology platform, PXP is used to develop autologous cell-based therapies for the in the vascular and orthopedic markets. Its device di …
  • CRA International Inc (CRAI):企業の財務・戦略的SWOT分析
    Summary CRA International Inc (CRA) is a consulting firm that offers economic, financial, and strategic expertise to law firms, corporations, accounting firms and governments. The firm provides services such as accounting and forensic services, antitrust and competition, auctions and competitive bid …
  • Accenture plc:企業の戦略・SWOT・財務分析
    Accenture plc - Strategy, SWOT and Corporate Finance Report Summary Accenture plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Xtant Medical Holdings Inc (XTNT)-製薬・医療分野:企業M&A・提携分析
    Summary Xtant Medical Holdings Inc (Xtant Medical), formerly Bacterin International Holdings, Inc. is a medical device company that develops regenerative medicine products and medical devices. The company’s products include 3Demin, osteosponge, osteosponge SC, osteoselect DBM Putty, OsteoSTX, osteow …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆